The orphan nuclear hormone receptor estrogen-related receptor A (ERRA, NR3B1) is a constitutive transcription factor that is structurally and functionally related to the classic estrogen receptors. ERRA can recognize both the estrogen response element and its own binding site (ERRE) in either dimeric or monomeric forms. ERRA is also a phosphoprotein whose expression in human breast tumors correlates with that of the receptor tyrosine kinase ErbB2, suggesting that its transcriptional activity could be regulated by signaling cascades. Here, we investigated growth factor regulation of ERRA function and found that it is phosphorylated in MCF-7 breast cancer cells in response to epidermal growth factor (EGF), an event that enhances its DNA binding. Interestingly, treatment with alkaline phosphatase shifts ERRA from a dimeric to a monomeric DNA-binding factor, and only the dimeric form interacts with the coactivator PGC-1A. In vitro, the DNA-binding domain of ERRA is selectively phosphorylated by protein kinase CD (PKCD), which increases its DNA-binding activity, whereas expression of constitutively active PKCD enhances TFF1 promoter activity via the ERRE. However, whereas treatment of MCF-7 cells with the phorbol ester phorbol-12-myristate 13-acetate also enhances ERRA activation of the TFF1 promoter reporter, it does not affect ERRA activity on its own promoter. In agreement, chromatin immunoprecipitation analysis shows that ERRA and RNA polymerase II are preferentially recruited to the TFF1 promoter after EGF treatment, whereas recruitment of these factors to its own promoter is not affected. These results reveal a mechanism through which growth factor signaling can selectively activate ERRA target genes in breast cancer cells. (Cancer Res 2005; 65(14): 6120-29)